aquatic veterinary Market

The Aquatic veterinary market is expected to grow from US$ 1.45 billion in 2022 to US$ 1.93 billion by 2030; the market is estimated to record a CAGR of 3.7% during 2022-2030.

The report highlights trends prevailing in the market and factors driving the market growth. The aquatic veterinary market size is growing with initiatives taken by various country governments to develop their respective aquaculture industries and the surging demand for food products derived from aquatic animals. Further, ongoing efforts for the development of novel fish vaccines are expected to create ample opportunities for the aquatic veterinary market in the coming years. However, stringent regulations for approval of vaccine is expected to hinder the overall market growth.

Technological Advancements in Fish Vaccine is likely to Favor the Growth of the Aquatic Veterinary Market

Diversifying into new fish species, particularly marine fish, is a trend in the aquaculture sector. Farms across the world are increasingly relying on vaccinations to manage animal health. The development of novel pathogens with extensive antigenic diversity may also reduce the effectiveness of conventional vaccines. This motivates vaccine researchers to look into new techniques for creating potent vaccines for aquaculture. Subunit or recombinant DNA/RNA particle vaccines may have been created using modern vaccine technology, which is focused on specific pathogen components. Finding new vaccine candidates to fight fish pathogens such as mycotic and parasitic agents is made possible by recent advancements in vaccines and vaccinology. The development and production of fish vaccines can do rapidly with the help of new techniques in genetics, immunology, and biotechnology. These techniques include the use of genetically engineered vectors, recombinant vaccines, and DNA vaccines.

DNA vaccine technology provides significant protection against fish diseases. Targeting the construct and/or transgene to antigen-receptor cells is a promising way to improve the DNA vaccine's effectiveness against other viral diseases. Molecular assemblies can be used to target dendritic cells (DC) and antigen-presenting cells (APC) in DNA vaccines, producing immune responses as a result. Another tactic is to encapsulate the DNA vaccine in specific carriers to increase transgene and MHC expression.

The development of novel vaccines known as recombinant DNA-based vaccine or new-generation vaccines has made extensive use of RDNA technology. Recombinant immunogenic protein vaccines or epitopes purified from vectors carrying the gene of interest produced in prokaryotic or eukaryotic expression systems, peptide vaccines, live vaccines produced by defined genetic manipulations, and microbial vectors carrying gene coding for immunogenic protein and DNA vaccines are among the types of vaccines based on recombinant DNA technology that have been developed. Recombinant vaccines have the advantage of closely simulating naturally occurring infections, which aids in triggering a potent immune response in the treated fish. They can also be mass-produced easily.

Report Segmentation and Scope -

The aquatic veterinary market is segmented on the basis of type, disease source, species, and route of administration. Based on type, the market is bifurcated into diagnostics and treatments. In terms of species, the aquatic veterinary market is segmented into fish, crustaceans, mollusks, and others. The aquatic veterinary market, by disease source, is segmented into bacteria, viruses, parasites, and others. Based on the administration route, the market is classified into water medication, medicated feed, and others.

The aquatic veterinary market, based on type, is segmented into diagnostics and treatments. In 2022, the treatment segment accounted for a larger share of the market. The market for this segment is expected to grow at a higher CAGR from 2022 to 2030. Aquatic animals can be immunized by injection, intramuscularly or intraperitoneally, and orally by mixing vaccines with feed by top dressing or mixing into feed as an ingredient. Fish vaccines are advantageous over antibiotics since they are natural biological materials that leave no residue in the product or environment and will not induce a resistant strain of the disease organism.

Based on species, the aquatic veterinary market is categorized into fish, crustaceans, mollusks, and others. The fish segment held the largest share of the market in 2022. It is expected to register the highest CAGR from 2022 to 2030.

In terms of disease source, the aquatic veterinary market is categorized into bacteria, viruses, parasites, and others. The bacteria segment held the largest share of the market in 2022. It is projected to register the highest CAGR during 2022-2030.

The aquatic veterinary market, by the route of administration, is categorized into water medication, medicated feed, and others. The water medication segment accounted for the largest share of the market in 2022. The same segment is projected to register the highest CAGR from 2022 to 2030.

Competitive Landscape and Key Companies:

Esox, Zoetis, Elanco Animal Health, Merck KgaA, Virbac Animal Health, Phbro Animal Health Corporation, Aquatic Diagnostics Ltd, Thermo Fisher Scientific, Ceva, and HIPRA are among the top 10 companies in the aquatic veterinary market. These companies focus on presenting new high-tech products, technological advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.

Food and Agriculture Organization and World Aquaculture Society Organization are a few of the major primary and secondary sources referred to while preparing the report on the Aquatic veterinary market.